Opiant Licenses Intravail Drug Delivery Technology

Opiant Pharmaceuticals (OTCQB:OPNT) announced a global, exclusive licensing agreement providing Opiant access to Aegis’ Intravail drug delivery technology for all of Opiant’s opioid antagonist compounds.
As quoted in the press release:

“We are fortunate to be able to access Aegis’ proprietary Intravail® drug delivery technologies for applications that may benefit patients with addictions and eating disorders,” said Roger Crystal, M.D., Chief Executive Officer of Opiant. “Aegis’ Intravail® can improve the absorption of drugs delivered nasally and has been designated generally recognized as safe (GRAS).”

Edward T. Maggio, Chief Executive Officer of Aegis added, “The Intravail® non-invasive absorption enhancement technology is particularly well suited for the treatment of chronic relapsing brain diseases and will help ensure that Opiant Pharmaceuticals maintains its leaderhip position in this field. We are excited to support these important programs.”

Click here to read the full press release.

Source: globenewswire.com